“March-in” rights provision of Bayh-Dole Act becoming an issue in drug price control debate

A new study from the Information Technology & Innovation Foundation, “The Bayh-Dole Act’s Vital Importance to the U.S. Life-Sciences Innovation System,” is caught-up in the debate over drug price controls. Specifically, the issue is over something called “march-in rights.” According to the author of this article in IPWatchdog, some are arguing that the law authorizes the government to license competitors if a resulting product isn’t “reasonably priced.”

Stay connected with us on Twitter and LinkedIn. Article ideas and other suggestions should be sent to tballard@pyapc.com. Include the name and contact information (phone and email) for follow-up.